Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Utah Medical Products (UTMD) EBIT (2016 - 2025)

Utah Medical Products has reported EBIT over the past 16 years, most recently at -$6.5 million for Q4 2025.

  • Quarterly results put EBIT at -$6.5 million for Q4 2025, down 321.3% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (down 81.79% YoY), and the annual figure for FY2025 was $2.5 million, down 11.35%.
  • EBIT for Q4 2025 was -$6.5 million at Utah Medical Products, down from $2.6 million in the prior quarter.
  • Over the last five years, EBIT for UTMD hit a ceiling of $5.1 million in Q3 2022 and a floor of -$10.5 million in Q4 2023.
  • Median EBIT over the past 5 years was $3.9 million (2021), compared with a mean of $2.9 million.
  • Biggest five-year swings in EBIT: skyrocketed 168.28% in 2021 and later plummeted 321.3% in 2025.
  • Utah Medical Products' EBIT stood at $5.1 million in 2021, then dropped by 1.17% to $5.1 million in 2022, then crashed by 306.84% to -$10.5 million in 2023, then surged by 127.94% to $2.9 million in 2024, then plummeted by 321.3% to -$6.5 million in 2025.
  • The last three reported values for EBIT were -$6.5 million (Q4 2025), $2.6 million (Q3 2025), and $3.2 million (Q2 2025) per Business Quant data.